Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 30, 2019 - Issue 6
Submit an article Journal homepage
542
Views
18
CrossRef citations to date
0
Altmetric
Psoriasis

Biological treatment for psoriasis and the risk of herpes zoster: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)

Guy ShalomDepartment of Dermatology and Venereology, Soroka Medical Center, Beer-Sheva, Israel; View further author information
,
Luigi NaldiDepartment of Dermatology, Azienda Ospedaliera Papa Giovanni XXIII, Study Center of the Italian Group for Epidemiologic Research in Dermatology (GISED), Bergamo, Italy; View further author information
,
Mark LebwohlIcahn School of Medicine at Mount Sinai, New York, NY, USA; View further author information
,
Arjen NikkelsLiège University Hospital CHU, Liège, Belgium; View further author information
,
Elke M. G. J. de JongRadboud University Medical Centre, and Radboud University Nijmegen, Nijmegen, The Netherlands; View further author information
,
Steven FakharzadehJanssen Research & Development, LLC, Horsham, PA, USA; View further author information
,
Kavitha G. GoyalJanssen Scientific Affairs, LLC, Horsham, PA, USA; View further author information
,
Bhaskar SrivastavaJanssen Scientific Affairs, LLC, Horsham, PA, USA; View further author information
,
Wayne LangholffJanssen Research & Development, LLC, Horsham, PA, USA; View further author information
,
Claudia GalindoJanssen Research & Development, LLC, Horsham, PA, USA; View further author information
&
Arnon D. CohenSiaal Research Center for Family Medicine and Primary Care, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel; ;Clalit Health Services, Tel Aviv, IsraelCorrespondence[email protected]
View further author information
 show all
Pages 534-539 | Received 13 Nov 2017, Accepted 02 Feb 2018, Published online: 06 Jun 2019

References

  • Schmader KE, Sloane R, Pieper C, et al. The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults. Clin J Pain. 2007;23:490–496.
  • Yawn BP, Saddier P, Wollan PC, et al. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82:1341–1349.
  • Pinchinat S, Cebrián-Cuenca AM, Bricout H, et al. Similar herpes zoster incidence across Europe: results from a systematic literature review. BMC Infect Dis. 2013;13:170.
  • Harpaz R, Ortega-Sanchez IR, Seward JF. Advisory Committee on Immunization Practices (ACIP) Department of Health and Human Services Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008; 57:1–30.
  • Gnann JW Jr, Whitley RJ. Clinical practice. Herpes zoster. N Engl J Med. 2002;347:340–346.
  • Desai RJ, Thaler KJ, Mahlknecht P, et al. Comparative risk of harm associated with the use of targeted immunomodulators: a systematic review. Arthritis Care Res (Hoboken). 2016;68:1078–1088.
  • Pérez-Sola MJ, Torre-Cisneros J, Pérez-Zafrilla B, et al. Infections in patients treated with tumour necrosis factor antagonists: incidence, etiology and mortality in the BIOBADASER registry. Med Clin (Barc). 2011;137:533–540.
  • Kim SY, Solomon DH. Tumor necrosis factor blockade and the risk of viral infection. Nat Rev Rheumatol. 2010;6:165–174.
  • Galloway JB, Mercer LK, Moseley A, et al. Risk of skin and soft tissue infections (including shingles) in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2013;72:229–234.
  • Smitten AL, Choi HK, Hochberg MC, et al. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum. 2007;57:1431–1438.
  • Serac G, Tubach F, Mariette X, et al. Risk of herpes zoster in patients receiving anti-TNF-α in the prospective French RATIO registry. J Invest Dermatol. 2012;132:726–729.
  • Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biological agents. Arthritis Rheum. 2005;52:3403–3412.
  • Failla V, Jacques J, Castronovo C, et al. Herpes zoster in patients treated with biologicals. Dermatology (Basel). 2012;224:251–256.
  • Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA. 2009;301:737–744.
  • Winthrop KL, Baddley JW, Chen L, et al. Association between the initiation of anti-TNF therapy and the risk of herpes zoster. JAMA. 2013;309:887–895.
  • McDonald JR, Zeringue AL, Caplan L, et al. Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis. Clin Infect Dis. 2009;48:1364–1371.
  • Dreiher J, Kresch FS, Comaneshter D, et al. Risk of herpes zoster in patients with psoriasis treated with biologic drugs. J Eur Acad Dermatol Venereol. 2012;26:1127–1132.
  • Shalom G, Zisman D, Bitterman H, et al. Systemic therapy for psoriasis and the risk of herpes zoster: a 500,000 person-year study. JAMA Dermatol. 2015;151:533–538.
  • Wolfe F, Michaud K, Chakravarty EF. Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders. Rheumatology (Oxford). 2006;45:1370–1375.
  • Papp KA, Strober B, Augustin M, et al. PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving or are candidates for, conventional systemic treatments or biologic agents. J Drugs Dermatol. 2012;11:1210–1217.
  • Kimball AB, Leonardi C, Stahle M, et al. Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicenter, prospective, disease-based registry (PSOLAR). Br J Dermatol. 2014;171:137–147.
  • Johnson BH, Palmer L, Gatwood J, et al. Annual incidence rates of herpes zoster among an immunocompetent population in the United States. BMC Infect Dis. 2015;15:502–506.
  • Insinga RP, Itzler RF, Pellissier JM, et al. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med. 2005;20:748–753.
  • Izurieta HS, Wernecke M, Kelman J, et al. Effectiveness and duration of protection provided by the live-attenuated herpes zoster vaccine in the medicare population ages 65 years and older. Clin Infect Dis. 2017;64:785–793.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.